Regarding the January 2021 article, Vu M, et al. Antihypertensive Deprescribing in Older Adult Veterans at End of Life Admitted to Veteran Affairs Nursing Homes. J Am Med Dir Assoc 2021 Jan;22(1):132-140.e5.
The authors have discovered some minor errors in Figure 1, Tables 1 and 2, and the accompanying manuscript text. These errors do not affect the substantive findings of the study or the discussion. Corrections are shown in bold text.
In Figure 1, the number diagnosed with hypertension should be 50,281 (the reported percentage in this box of 85.6% is correct). The percent with at least 1 blood pressure medication the day of or on the day before BP measurement is 65.5% (the reported n = 32,923 is correct). Finally, the first line of the results section should state that, of the 30,940 residents with LLE/AD and HTN and at least 7 days of follow-up time, 34.2% met criteria for our final sample with potentially overtreated HTN, consistent with Figure 1.
Corrected data in Table 1 include the following:
|Distance from next of kin ZIP code centroid to CLC|
|Quartile 4 >93.2 miles (150 km)||2547 (24.1)|
|Renal failure||1781 (16.8)|
|Presence of infection||2785 (26.3)|
|Falls or fractures in past 180 days|
The labels for alpha blockers and ACE/ARB in Table 2 should be switched as shown below. 37.3% of the sample were treated with ACE/ARBs at baseline, and 15.8% with alpha blockers.
|Overall||Intensity of Overtreatment|
|LSBP and 1 class||VLSBP and 1 class||LSBP and >1 class||VLSBP and >1 class|
|Most common antihypertensive classes (column %)|
In the text of the results section “Competing Risk Models: Factors Associated with Antihypertensive Deprescribing”, the correct estimates for dependent/total dependence with ADL compared to least dependent is aHRSD 1.12 (95% CI 1.03, 1.23), for pain is aHRSD 1.13, 95% CI 1.05, 1.21), and for FY2015 is aHRSD 1.27, 95% CI 1.09, 1.47, as shown in Figure 3 and Supplementary Table 2.
The authors regret these errors and apologize for the inconvenience.
Published online: June 08, 2021
Published by Elsevier Inc. on behalf of AMDA - The Society for Post-Acute and Long-Term Care Medicine.
ScienceDirectAccess this article on ScienceDirect
- Antihypertensive Deprescribing in Older Adult Veterans at End of Life Admitted to Veteran Affairs Nursing HomesJournal of the American Medical Directors AssociationVol. 22Issue 1
- PreviewGeriatric palliative care approaches support deprescribing of antihypertensives in older nursing home (NH) residents with limited life expectancy and/or advanced dementia (LLE/AD) who are intensely treated for hypertension (HTN), but information on real-world deprescribing patterns in this population is limited. We examined the incidence and factors associated with antihypertensive deprescribing.